- Home
- WRLD vs KALV Comparison
WRLD vs KALV Comparison
Compare WRLD & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- KALV
- Stock Information
- Founded
- WRLD 1962
- KALV N/A
- Country
- WRLD United States
- KALV United States
- Employees
- WRLD N/A
- KALV N/A
- Industry
- WRLD Finance: Consumer Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- KALV Health Care
- Exchange
- WRLD Nasdaq
- KALV Nasdaq
- Market Cap
- WRLD 683.3M
- KALV 551.2M
- IPO Year
- WRLD 1991
- KALV N/A
- Fundamental
- Price
- WRLD $152.50
- KALV $13.32
- Analyst Decision
- WRLD
- KALV Strong Buy
- Analyst Count
- WRLD 0
- KALV 8
- Target Price
- WRLD N/A
- KALV $26.43
- AVG Volume (30 Days)
- WRLD 69.3K
- KALV 1.3M
- Earning Date
- WRLD 10-23-2025
- KALV 11-10-2025
- Dividend Yield
- WRLD N/A
- KALV N/A
- EPS Growth
- WRLD N/A
- KALV N/A
- EPS
- WRLD 10.75
- KALV N/A
- Revenue
- WRLD $570,762,378.00
- KALV $1,426,000.00
- Revenue This Year
- WRLD $0.89
- KALV N/A
- Revenue Next Year
- WRLD $3.51
- KALV $234.65
- P/E Ratio
- WRLD $14.27
- KALV N/A
- Revenue Growth
- WRLD 2.33
- KALV N/A
- 52 Week Low
- WRLD $104.99
- KALV $7.30
- 52 Week High
- WRLD $185.48
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- WRLD 59.25
- KALV 58.50
- Support Level
- WRLD $131.00
- KALV $12.82
- Resistance Level
- WRLD $140.69
- KALV $13.75
- Average True Range (ATR)
- WRLD 7.00
- KALV 0.88
- MACD
- WRLD 3.31
- KALV 0.13
- Stochastic Oscillator
- WRLD 95.93
- KALV 64.25
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.